Chronic hepatitis B: A wave of new therapies on the horizon

Adam, 2002, Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men, Cancer Res., 62, 3609 Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N. Eng. J. Med., 370, 1483, 10.1056/NEJMoa1316366 Arends, 2014, Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians, Gut Arrowhead, 2015b. Arrowhead Provides Update on IND for ARC-520 Phase 2b Study. Aspinall, 2011, Hepatitis B prevention, diagnosis, treatment and care: a review, Occup. Med. (Lond.), 61, 531, 10.1093/occmed/kqr136 Bedossa, 2015, Reversibility of hepatitis B virus cirrhosis after therapy: who and why?, Liver Int., 35, 78, 10.1111/liv.12710 Bertoletti, 2007, Immune response and tolerance during chronic hepatitis B virus infection, Hepatol. Res., 37, S331, 10.1111/j.1872-034X.2007.00221.x Bertoletti, 2013, Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?, PLoS Pathog., 9, e1003784, 10.1371/journal.ppat.1003784 Bertoletti, 2014, The immune tolerant phase of chronic HBV infection: new perspectives on an old concept, Cell. Mol. Immunol. Block, 2013, Chronic hepatitis B: what should be the goal for new therapies?, Antiviral Res., 98, 27, 10.1016/j.antiviral.2013.01.006 Block, 2007, Molecular virology of hepatitis B virus for clinicians, Clin. Liver Dis., 11, 685, 10.1016/j.cld.2007.08.002 Block, 2003, Molecular viral oncology of hepatocellular carcinoma, Oncogene, 22, 5093, 10.1038/sj.onc.1206557 Blumberg, 1965, A “New” antigen in leukemia sera, JAMA: J. Am. Med. Assoc., 191, 541, 10.1001/jama.1965.03080070025007 Blumberg, 1967, A serum antigen (Australia antigen) in Down’s Syndrome leukemia and hepatitis, Ann. Int. Med., 66, 924, 10.7326/0003-4819-66-5-924 Brouwer, 2015, Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study), Hepatology, 61, 1512, 10.1002/hep.27586 Cai, 2014, Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity, Antiviral Res., 108, 48, 10.1016/j.antiviral.2014.05.007 Cai, 2012, Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation, Antimicrob. Agents Chemother., 56, 4277, 10.1128/AAC.00473-12 Campagna, 2013, Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids, J. Virol., 87, 6931, 10.1128/JVI.00582-13 Chae, 2007, Time for an active antiviral therapy for hepatitis B: an update on the management of hepatitis B virus infection, Ther. Clin. Risk Manag., 3, 605 Chan, 2011, Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report, J. Hepatol., 55, 1121, 10.1016/j.jhep.2011.06.006 Chang, 2012, The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy, Antiviral Res., 96, 405, 10.1016/j.antiviral.2012.10.001 Chang, 2006, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, N. Eng. J. Med., 354, 1001, 10.1056/NEJMoa051285 Cho, 2014, Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease, Gut, 10.1136/gutjnl-2013-306409 Coffin, 2011, Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy, J. Viral Hepat., 18, 415, 10.1111/j.1365-2893.2010.01321.x Curry, 2015, Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study, Gastroenterology, 148, e101 Day, 2006, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, 443, 350, 10.1038/nature05115 Deres, 2003, Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids, Science, 299, 893, 10.1126/science.1077215 Dong, 2015, Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication, Antiviral Res., 118, 110, 10.1016/j.antiviral.2015.03.015 Dougherty, 2007, A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion, Antimicrob. Agents Chemother., 51, 4427, 10.1128/AAC.00541-07 EASL, 2012, EASL clinical practice guidelines: management of chronic hepatitis B virus infection, J. Hepatol., 57, 167, 10.1016/j.jhep.2012.02.010 Ebert, 2015, Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis, Proc. Natl. Acad. Sci. U.S.A. Ebert, 2015, Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus, Proc. Natl. Acad. Sci. U.S.A. El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, e1261 El-Serag, 2007, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology, 132, 2557, 10.1053/j.gastro.2007.04.061 Gaggar, 2014, Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study, Vaccine, 32, 4925, 10.1016/j.vaccine.2014.07.027 Gane, 2015, The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection, J. Hepatol., 10.1016/j.jhep.2015.02.037 Ganem, 2004, Hepatitis B virus infection–natural history and clinical consequences, N. Eng. J. Med., 350, 1118, 10.1056/NEJMra031087 Gardiner, 2013, A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection, PLoS ONE, 8, e63818, 10.1371/journal.pone.0063818 George, R., 2014. Chimigen® HBV therapeutic vaccine: a novel dendritic cell receptor-targeted immunotherapy for treating chronic Hepatitis B virus infection, $th World Congress on Virology, HIlton San Antonio Airport, TX, USA. Gish, 2010, A multidisciplinary approach to the management of hepatocellular carcinoma, Gastroenterol. Hepatol., 6, 1 Gordon, 2014, Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population, Clin. Gastroenterol. Hepatol., 12, 885, 10.1016/j.cgh.2013.09.062 Gripon, 2005, Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein, J. Virol., 79, 1613, 10.1128/JVI.79.3.1613-1622.2005 Grogan, K., 2013. Medivir and Daewoong pull plug on hepatitis B drug. PharmaTimes Digital. Guo, 2015, STING agonists induce an innate antiviral immune response against hepatitis B virus, Antimicrob. Agents Chemother., 59, 1273, 10.1128/AAC.04321-14 Halperin, 2006, Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults, Vaccine, 24, 20, 10.1016/j.vaccine.2005.08.095 Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 Hoofnagle, 2009, Reactivation of hepatitis B, Hepatology, 49, S156, 10.1002/hep.22945 Hoofnagle, 2007, Management of hepatitis B: summary of a clinical research workshop, Hepatology, 45, 1056, 10.1002/hep.21627 Hoofnagle, 2014, Therapy for hepatitis C – the costs of success, N. Eng. J. Med., 370, 1552, 10.1056/NEJMe1401508 Hostetler, 2009, Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art, Antiviral Res., 82, A84, 10.1016/j.antiviral.2009.01.005 Jaroszewicz, 2010, Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective, J. Hepatol., 52, 514, 10.1016/j.jhep.2010.01.014 Kanwal, 2015, Surveillance for hepatocellular carcinoma: can we focus on the mission?, Clin. Gastroenterol. Hepatol., 13, 805, 10.1016/j.cgh.2014.12.016 Katen, 2013, Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure, Structure, 21, 1406, 10.1016/j.str.2013.06.013 Kennedy, 2015, Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease, Virology, 476, 196, 10.1016/j.virol.2014.12.001 Khan, 2012, HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications, Immunol. Cell Biol., 90, 85, 10.1038/icb.2011.100 Kim, 2012, Efficacy of thymosin alpha-1 plus peginterferon alpha-2a combination therapy compared with peginterferon alpha-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study, Scand. J. Gastroenterol., 47, 1048, 10.3109/00365521.2012.694902 Kowdley, 2014, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N. Eng. J. Med., 370, 1879, 10.1056/NEJMoa1402355 Lanford, 2013, GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees, Gastroenterology, 144, 1508, 10.1053/j.gastro.2013.02.003 Lau, 2005, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, N. Eng. J. Med., 352, 2682, 10.1056/NEJMoa043470 Lee, 2008, Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study, J. Gastroenterol. Hepatol., 23, 729, 10.1111/j.1440-1746.2008.05387.x Lee, 2013, Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection, Antimicrob. Agents Chemother., 57, 6325, 10.1128/AAC.01742-13 Liaw, 1999, Functions of the extracellular matrix and matrix degrading proteases during tumor progression, Braz. J. Med. Biol. Res., 32, 805, 10.1590/S0100-879X1999000700002 Liaw, 2012, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hep. Intl., 6, 531, 10.1007/s12072-012-9365-4 Liaw, 2008, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatol. Int., 2, 263, 10.1007/s12072-008-9080-3 Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N. Eng. J. Med., 351, 1521, 10.1056/NEJMoa033364 Lin, 2014, The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Molecular therapy, Nucleic Acids, 3, e186, 10.1038/mtna.2014.38 Liu, 2013, Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes, PLoS Pathog., 9, e1003613, 10.1371/journal.ppat.1003613 Lobritz, 2010, HIV-1 entry, inhibitors, and resistance, Viruses, 2, 1069, 10.3390/v2051069 Locarnini, S., 2004. Molecular virology of hepatitis B virus. Lok, 2004, Prevention of hepatitis B virus-related hepatocellular carcinoma, Gastroenterology, 127, S303, 10.1053/j.gastro.2004.09.045 Lok, 2011, Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?, J. Gastroenterol. Hepatol., 26, 221, 10.1111/j.1440-1746.2010.06576.x Lok, 2009, Chronic hepatitis B: update 2009, Hepatology, 50, 661, 10.1002/hep.23190 Lok, 2012, Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable, Ann. Intern. Med., 156, 743, 10.7326/0003-4819-156-10-201205150-00013 Mahtab MA, B.M., Vaillant A, 2015. Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection. Mao, 2011, Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells, J. Virol., 85, 1048, 10.1128/JVI.01998-10 Membreno, 2013, Cyclophilin inhibitors for hepatitis C therapy, Clin. Liver Dis., 17, 129, 10.1016/j.cld.2012.09.008 Menendez-Arias, 2014, Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance, Curr. Opin. Virol., 8, 1, 10.1016/j.coviro.2014.04.005 Michalak, 2009, Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B, Antimicrob. Agents Chemother., 53, 3803, 10.1128/AAC.00263-09 Michel, 2015, Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?, Med. Microbiol. Immunol., 204, 121, 10.1007/s00430-014-0381-y Nkongolo, 2014, Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor, J. Hepatol., 60, 723, 10.1016/j.jhep.2013.11.022 Noordeen, 2013, Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro, Antimicrob. Agents Chemother., 57, 5291, 10.1128/AAC.01003-13 Norton, 2010, Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks, Hepatology, 52, 1242, 10.1002/hep.23806 O’Neill, 2013, Suppression of survival signalling pathways by the phosphatase PHLPP, FEBS J., 280, 572, 10.1111/j.1742-4658.2012.08537.x Obeng-Adjei, 2012, Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver, Cancer Gene Ther., 19, 779, 10.1038/cgt.2012.61 Painter, 2007, Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections, Antimicrob. Agents Chemother., 51, 3505, 10.1128/AAC.00460-07 Pawlotsky, 2014, New hepatitis C therapies: the toolbox, strategies, and challenges, Gastroenterology, 146, 1176, 10.1053/j.gastro.2014.03.003 Pellicelli, 2008, Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study, Clin. Ther., 30, 317, 10.1016/j.clinthera.2008.02.012 Peng, 2008, PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients, Mol. Immunol., 45, 963, 10.1016/j.molimm.2007.07.038 Peters, 2004, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B, Gastroenterology, 126, 91, 10.1053/j.gastro.2003.10.051 Petersen, 2008, Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein, Nat. Biotechnol., 26, 335, 10.1038/nbt1389 Phillips, 2015, Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production, Gastroenterology, 148, e407 Plotkin, 2013, A hepatitis B vaccine with a novel adjuvant, Vaccine, 31, 5297, 10.1016/j.vaccine.2013.09.019 Reddy, 2008, Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B, J. Med. Chem., 51, 666, 10.1021/jm7012216 Roethle, 2013, Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis, J. Med. Chem., 56, 7324, 10.1021/jm400815m Saruc, 2003, Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B, J. Pharm. Sci., 92, 1386, 10.1002/jps.10401 Sato, 2015, The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus, Immunity, 42, 123, 10.1016/j.immuni.2014.12.016 Schickli, 2015, Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge, J. Clin. Investig., 125, 1637, 10.1172/JCI78450 Seeger, 2000, Hepatitis B virus biology, Microbiol. Mol. Biol. Rev., 64, 51, 10.1128/MMBR.64.1.51-68.2000 Seeger, 2014, Targeting hepatitis B virus with CRISPR/Cas9. Molecular therapy, Nucleic Acids, 3, e216, 10.1038/mtna.2014.68 Seigal, 2015, The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity, J. Med. Chem., 58, 2855, 10.1021/jm501892g Seto, 2014, Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study, J. Clin. Oncol., 32, 3736, 10.1200/JCO.2014.56.7081 Simsek, 2009, Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I, Virology, 384, 12, 10.1016/j.virol.2008.11.027 Smith, 2007, Do prodrugs deliver?, Curr. Opin. Drug Discov. Devel., 10, 550 Springbank, SB 9200 HCV. Spring Bank Parmaceuticals. Stray, 2005, A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly, Proc. Natl. Acad. Sci. U.S.A., 102, 8138, 10.1073/pnas.0409732102 Stray, 2006, BAY 41–4109 has multiple effects on Hepatitis B virus capsid assembly, J. Mol. Recognit., 19, 542, 10.1002/jmr.801 Tavis, 2015, The hepatitis B virus ribonuclease H as a drug target, Antiviral Res., 118, 132, 10.1016/j.antiviral.2015.04.002 Tsai, 2003, Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications, J. Biomed. Sci., 10, 120, 10.1007/BF02256004 Tzeng, 2012, PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model, PLoS ONE, 7, e39179, 10.1371/journal.pone.0039179 Urban, 2014, Strategies to inhibit entry of HBV and HDV into hepatocytes, Gastroenterology, 147, 48, 10.1053/j.gastro.2014.04.030 Uribe, 2014, Current treatment guidelines for chronic hepatitis B and their applications, J. Clin. Gastroenterol., 48, 773, 10.1097/MCG.0000000000000130 Wang, 2012, In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations, Antivir. Ther., 17, 793, 10.3851/IMP2152 Ward, 2014, Hepatitis C virus: the 25-year journey from discovery to cure, Hepatology, 60, 1479, 10.1002/hep.27377 Weber, 2002, Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model, Antiviral Res., 54, 69, 10.1016/S0166-3542(01)00216-9 Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 West, 2014, New and emerging HDAC inhibitors for cancer treatment, J. Clin. Investig., 124, 30, 10.1172/JCI69738 Whitacre, 2009, Use of hepadnavirus core proteins as vaccine platforms, Expert Rev. Vaccines, 8, 1565, 10.1586/erv.09.121 Wooddell, 2013, Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection, Mol. Ther., 21, 973, 10.1038/mt.2013.31 Wu, 2013, Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly, Antimicrob. Agents Chemother., 57, 5344, 10.1128/AAC.01091-13 Wu, 2015, Thymosin alpha-1 treatment in chronic hepatitis B, Expert Opin. Biol. Ther., 1 Xing, 2012, T-cell tolerance: central and peripheral, Cold Spring Harb. Perspect. Biol., 4, 10.1101/cshperspect.a006957 Xu, 2013, Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings, J. Hepatol., 59, 450, 10.1016/j.jhep.2013.05.003 Xu, 2008, A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients, PLoS ONE, 3, e2565, 10.1371/journal.pone.0002565 Xu, 2009, HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells, Mol. Immunol., 46, 2640, 10.1016/j.molimm.2009.04.031 Yang, 2012, Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance, J. Med. Virol., 84, 424, 10.1002/jmv.23229 Yang, 2008, Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis, Antiviral Res., 77, 136, 10.1016/j.antiviral.2007.10.014 Yapali, 2014, Management of hepatitis B: our practice and how it relates to the guidelines, Clin. Gastroenterol. Hepatol., 12, 16, 10.1016/j.cgh.2013.04.036 You, 2001, A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B, World J. Gastroenterol., 7, 411, 10.3748/wjg.v7.i3.411 Yu, 2011, Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion, J. Med. Chem., 54, 5660, 10.1021/jm200696v Yuen, 2010, Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease, Hepatology, 51, 767, 10.1002/hep.23462 Yuen, 2011, Treatment of chronic hepatitis B: Evolution over two decades, J. Gastroenterol. Hepatol., 26, 138, 10.1111/j.1440-1746.2010.06545.x Zeisel, 2015, Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure, Gut, 10.1136/gutjnl-2014-308943 Zhang, 2013, Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B, Hepatobiliary Pancreat. Dis. Int., 12, 394, 10.1016/S1499-3872(13)60061-2 Zoulim, 2015, Antiviral therapies and prospects for a cure of chronic hepatitis B, Cold Spring Harb. Perspect. Med., 5, 10.1101/cshperspect.a021501 Zoulim, 2009, Hepatitis B virus resistance to nucleos(t)ide analogues, Gastroenterology, 137, e1591 Achillion Pharmaceuticals, I., 2010. <http://ir.achillion.com/releasedetail.cfm?releaseid=441884>. Alnylam, 2014. Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees. <http://investors.alnylam.com/releasedetail.cfm?ReleaseID=847055>. Altravax, Hepatitis B Virus (HBV) vaccine. <http://www.altravax.com/?page_id=108>. Arrowhead, 2015a. Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520. <http://ir.arrowheadresearch.com/releasedetail.cfm?releaseid=906108>. Benitech Biopharma. Hepatitis B. <http://www.benitec.com/pipeline/in-house-programs-detail#hepb>. Contravir, CMX157 Overview. <http://contravir.com/cmx157/>. DYNAVAX, 2011. Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate. <http://investors.dynavax.com/releasedetail.cfm?releaseid=551782>. HEC. <http://www.hecpharm.com/research-and-development/pipeline.html#.VWiowyj9vKM>. Hepatera, 2014. Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta, PR Newswire. <http://www.prnewswire.com/news-releases/maxwell-biotech-portfolio-company-hepatera-announces-proof-of-concept-clinical-results-with-myrcludex-b-a-novel-entry-inhibitor-for-treatment-of-chronic-hepatitis-b-and-delta-279878112.html>. Inovio, 2015. INO-1800 SynCon® immunotherapy for hepatitis B virus. <http://www.inovio.com/products/infectious-disease-vaccines/hepatitis/hbv/>. TetraLogic, Birinapant. <http://tetralogicpharma.com/birinapant/>.